Ainuovirine

Antiretroviral drug

Ainuovirine
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Ainuovirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was investigated for its potential use in the treatment of HIV/AIDS. It belongs to a class of antiretroviral drugs that target the reverse transcriptase enzyme, which is crucial for the replication of the HIV virus.

Mechanism of Action

Ainuovirine functions by binding to the reverse transcriptase enzyme of the HIV virus. This binding induces a conformational change in the enzyme, thereby inhibiting its activity. Unlike nucleoside reverse transcriptase inhibitors (NRTIs), which mimic the natural substrates of the enzyme, NNRTIs like Ainuovirine bind to a distinct site on the enzyme, known as the NNRTI pocket. This allosteric inhibition prevents the conversion of viral RNA into DNA, a critical step in the viral replication cycle.

Pharmacokinetics

The pharmacokinetic profile of Ainuovirine includes its absorption, distribution, metabolism, and excretion. As an orally administered drug, Ainuovirine is absorbed through the gastrointestinal tract. It is then distributed throughout the body, with a particular affinity for tissues where HIV replication is active. The drug is metabolized primarily in the liver, and its metabolites are excreted via the renal and biliary systems.

Clinical Development

Ainuovirine was subject to clinical trials to evaluate its efficacy and safety in the treatment of HIV infection. However, like many investigational drugs, it faced challenges in demonstrating sufficient clinical benefit over existing therapies. The development of Ainuovirine was eventually discontinued, as newer NNRTIs with improved efficacy and safety profiles became available.

Side Effects

As with other NNRTIs, Ainuovirine was associated with certain side effects. Common adverse effects included rash, nausea, and headache. More severe reactions, although rare, could include hepatotoxicity and hypersensitivity reactions. Monitoring of liver function tests was recommended during its use in clinical trials.

Resistance

Resistance to NNRTIs, including Ainuovirine, can develop through mutations in the reverse transcriptase enzyme. These mutations alter the NNRTI binding site, reducing the drug's efficacy. Cross-resistance among NNRTIs is a significant concern, necessitating careful selection of antiretroviral regimens in patients with resistant HIV strains.

Related Pages

• HIV/AIDS
• Antiretroviral drug
• Reverse transcriptase inhibitor
• Non-nucleoside reverse transcriptase inhibitor